| 2025年中报 | 2024年年报 | 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 临床后期及商业化业务(元) | 1,082,553,188.20 | 2,010,067,122.51 | 957,014,461.99 | 2,872,916,749.70 | 1,988,773,673.67 |
| 临床早期业务(元) | 417,407,524.72 | 729,544,523.70 | 342,767,214.37 | 644,586,477.25 | 296,794,829.19 |
| 新兴业务(元) | 115,169,184.71 | 242,559,405.50 | - | - | - |
| 其他产品(元) | - | 29,795,302.61 | - | 149,913,895.54 | - |
| 营业成本(元) | |||||
| 临床后期及商业化业务(元) | 637,611,754.25 | 1,217,914,335.26 | 593,555,552.12 | 1,388,649,568.20 | 909,679,353.61 |
| 临床早期业务(元) | 310,694,157.33 | 624,782,629.95 | 321,115,104.42 | 590,278,274.06 | 245,952,312.75 |
| 新兴业务(元) | 223,433,909.76 | 416,885,067.33 | - | - | - |
| 其他产品(元) | - | 11,779,156.43 | - | 196,285,255.01 | - |
| 毛利(元) | |||||
| 临床后期及商业化业务(元) | 444,941,433.95 | 792,152,787.25 | 363,458,909.87 | 1,484,267,181.50 | 1,079,094,320.06 |
| 临床早期业务(元) | 106,713,367.39 | 104,761,893.75 | 21,652,109.95 | 54,308,203.19 | 50,842,516.44 |
| 新兴业务(元) | -108,264,725.05 | -174,325,661.83 | - | - | - |
| 其他产品(元) | - | 18,016,146.18 | - | -46,371,359.47 | - |
| 毛利率(%) | |||||
| 临床后期及商业化业务(%) | 41.10 | 39.41 | 37.98 | 51.66 | 54.26 |
| 临床早期业务(%) | 25.57 | 14.36 | 6.32 | 8.43 | 17.13 |
| 新兴业务(%) | -94.00 | -71.87 | - | - | - |
| 其他产品(%) | - | 60.47 | - | -30.93 | - |
| 收入构成(%) | |||||
| 临床后期及商业化业务(%) | 67.03 | 66.74 | 73.63 | 78.34 | 87.01 |
| 临床早期业务(%) | 25.84 | 24.22 | 26.37 | 17.58 | 12.99 |
| 新兴业务(%) | 7.13 | 8.05 | - | - | - |
| 其他产品(%) | - | 0.99 | - | 4.09 | - |
| 毛利构成(%) | |||||
| 临床后期及商业化业务(%) | 100.35 | 106.96 | 94.38 | 99.47 | 95.50 |
| 临床早期业务(%) | 24.07 | 14.15 | 5.62 | 3.64 | 4.50 |
| 新兴业务(%) | -24.42 | -23.54 | - | - | - |
| 其他产品(%) | - | 2.43 | - | -3.11 | - |